| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Cilastatin (formerly MK791; MK-0791; Recarbrio) is a renal dehydropeptidase inhibitor and a leukotriene D4 dipeptidase inhibitor with nephroprotective effects. Dehydropeptidase is an enzyme found in the kidney and is responsible for degrading the antibiotic imipenem.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
Without lessening the antimicrobial effect of Vancomycin, ciplastatin (200 μg/mL; 24 hours; RPTECs) treatment prevents Vancomycin-induced proximal tubule apoptosis and boosts cell viability[2].
|
| ln Vivo |
In a mouse model of systemic infection (female mice, strain CD-1, 20 g), Imipenem plus Cilastatin can shield mice against infections with S. aureus, E. coli, and P. aeruginosa[3].
|
| References |
|
| Molecular Formula |
C16H26N2O5S
|
|---|---|
| Molecular Weight |
358.45
|
| Exact Mass |
358.16
|
| Elemental Analysis |
C, 53.61; H, 7.31; N, 7.82; O, 22.32; S, 8.95
|
| CAS # |
82009-34-5
|
| Related CAS # |
Cilastatin sodium;81129-83-1;Cilastatin-15N,d3;2738376-83-3
|
| Appearance |
Solid powder
|
| SMILES |
[C@H]1(C(C1)(C)C)C(=O)N/C(=C\CCCCSC[C@@H](C(=O)O)N)C(=O)O
|
| InChi Key |
DHSUYTOATWAVLW-WFVMDLQDSA-N
|
| InChi Code |
InChI=1S/C16H26N2O5S/c1-16(2)8-10(16)13(19)18-12(15(22)23)6-4-3-5-7-24-9-11(17)14(20)21/h6,10-11H,3-5,7-9,17H2,1-2H3,(H,18,19)(H,20,21)(H,22,23)/b12-6-/t10-,11+/m1/s1
|
| Chemical Name |
2-Heptenoic acid, 7-((2-amino-2-carboxyethyl)thio)-2-(((2,2-dimethylcyclopropyl)carbonyl)amino)-, (R-(R*,S*-(Z)))-
|
| Synonyms |
MK 791; M K-791; MK0791; MK791;Cilastatin; MK 0791; MK-0791;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 72~100 mg/mL (200.86~278.98 mM )
1M NaOH : ~100 mg/mL (~278.98 mM) H2O : 7~12.5 mg/mL (~34.87 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (7.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.75 mg/mL (7.67 mM) Solubility in Formulation 5: 20 mg/mL (55.80 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7898 mL | 13.9489 mL | 27.8979 mL | |
| 5 mM | 0.5580 mL | 2.7898 mL | 5.5796 mL | |
| 10 mM | 0.2790 mL | 1.3949 mL | 2.7898 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
